GeoVax Labs logo
GeoVax Labs GOVX
$ 0.35 -6.75%

Quarterly report 2025-Q3
added 11-13-2025

report update icon

GeoVax Labs Income Statement 2011-2025 | GOVX

Annual Income Statement GeoVax Labs

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.72 M 758 K 10.8 M 6.47 M 39.3 K 4.16 M 3.08 M 2.54 M 2.4 M 5.73 T 10.4 T 12.8 T 13.7 T

Shares

1.82 M 1.13 M 6.1 M 1.38 M 60.4 K 160 70 40 30 26.6 M 21.2 M 18.3 M 15.7 M

Historical Prices

2.6 0.67 1.77 5.1 - - - - - - - - -

Net Income

-26 M -14 M -18.6 M -2.96 M -2.37 M -2.56 M -2.17 M -3.27 M -2.69 M -2.73 M -2.28 M -2.14 M -2.35 M

Revenue

- 81.5 K 386 K 1.82 M 1.18 M 963 K 1.08 M 829 K 428 K 883 K 2.42 M 2.66 M 4.9 M

Gross Profit

- - - - - - - - - 883 K 2.42 M 2.66 M 4.9 M

Operating Income

-26.7 M -14 M -18.7 M -2.82 M -2.37 M -2.56 M -2.17 M -3.27 M -2.69 M -2.74 M -2.29 M -2.14 M -2.35 M

Interest Expense

- - 1.29 K 144 K 4.5 K 2.59 K - - - - - - -

EBITDA

-26.7 M -14 M -18.7 M -2.8 M -2.36 M -2.54 M -2.15 M -3.24 M -2.67 M -2.67 M -2.21 M -2.05 M -1.81 M

Operating Expenses

26.7 M 14.1 M 19.1 M - 3.55 M 3.53 M 3.25 M 4.1 M 3.12 M 3.62 M 4.71 M 4.8 M 7.25 M

General and Administrative Expenses

6.02 M 4.99 M 3.58 M 2.2 M 1.64 M 1.65 M 1.23 M 2.13 M 1.43 M 1.81 M 1.79 M 1.75 M 2.97 M

All numbers in USD currency

Quarterly Income Statement GeoVax Labs

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

20.3 M 15.4 M 12 M 10.5 M 6.4 M 2.54 M 2.37 M 1.98 M 1.77 M 1.56 M 1.76 M 26.3 M 23.5 M 12.7 M 7.11 M 6.38 M 6.35 M 6.32 M 5.33 M 3.83 M 783 K 691 K 234 K 15 K 331 328 246 219 335 K 310 K 248 K 107 M 67 M 59.8 M 55.4 M 55.2 M 44.3 M 37.4 M 34.6 M 32 M 32 M 32 M 32 M 32 M 25.3 M 25.1 M 32 M 23.8 M 21.7 M 21.1 M 20.2 M 18.7 M 18.5 M 17.8 M 16.7 M 16.4 M 15.8 M 15.7 M 16.4 M

Net Income

-6.32 M -5.37 M -5.36 M - -5.82 M -5.06 M -5.85 M - -8.41 M -5.93 M -4.04 M - -3.97 M -2.24 M -2.43 M - -1.95 M -1.31 M -1.56 M - -571 K -455 K -596 K - -424 K -654 K -701 K - -667 K -637 K -622 K - -589 K -517 K -548 K - -464 K -576 K -1.3 M -693 K -620 K -676 K -700 K -924 K -515 K -680 K -700 K -872 K -190 K -526 K -697 K -610 K -297 K -498 K -731 K -1.15 M -376 K -211 K -606 K

Revenue

- 852 K 1.64 M - 2.79 M 301 K - - - - - - - - 81.5 K - 30.4 K 79.7 K 110 K - 415 K 441 K 716 K - 333 K 210 K 364 K - 349 K 93.3 K 221 K - 248 K 352 K 296 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-6.37 M -5.42 M -5.41 M - -5.85 M -5.06 M -5.88 M - -8.6 M -6.18 M -4.27 M - -3.97 M -2.24 M -2.43 M - -1.95 M -1.49 M -1.56 M - -436 K -448 K -595 K - -426 K -654 K -702 K - -667 K -638 K -623 K - -590 K -518 K -549 K - -465 K -576 K -1.3 M - -621 K -678 K -702 K - -515 K -681 K -702 K - -191 K -527 K -698 K - -298 K -499 K -731 K - -376 K -212 K -607 K

Interest Expense

- - - - - - - - - - - - - - - - - 531 755 - 134 K 7.15 K 1.14 K - 1.05 K 1.09 K 1.13 K - 625 625 208 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -5.39 M - - - -5.86 M - - - -4.25 M - -3.93 M -2.24 M -2.42 M - -1.92 M -1.49 M -1.56 M - -433 K -441 K -594 K - -420 K -650 K -700 K - -652 K -628 K -618 K - -570 K -504 K -542 K - -443 K -562 K -1.29 M - -600 K -664 K -694 K - -465 K -648 K -685 K - -139 K -492 K -680 K - -228 K -452 K -708 K - -295 K -158 K -580 K

Operating Expenses

6.37 M 6.27 M 7.04 M - 8.64 M 5.36 M 5.88 M - 8.6 M 6.18 M 4.27 M - 3.97 M 2.24 M 2.51 M - 1.98 M 1.57 M 1.67 M - 852 K 889 K 1.31 M - 759 K 864 K 1.07 M - 1.02 M 731 K 844 K - 838 K 870 K 844 K - 905 K 742 K 1.34 M - 714 K 750 K 805 K - 837 K 861 K 805 K - 1.2 M 969 K 1.49 M - 936 K 1.2 M 1.59 M - 1.67 M 1.96 M 1.5 M

General and Administrative Expenses

1.33 M 1.54 M 1.69 M - 1.24 M 1.09 M 1.46 M - 1.65 M 1.46 M 1.45 M - 1.25 M 935 K 1.18 M - 757 K 733 K 1.07 M - 435 K 427 K 502 K - 291 K 413 K 510 K - 459 K 359 K 357 K - 340 K 352 K 293 K - 221 K 345 K 907 K - 336 K 365 K 401 K - 412 K 345 K 401 K - 316 K 19.6 K 219 K - 334 K 492 K 513 K - 583 K 579 K 662 K

All numbers in USD currency

The income statement is one of the three key financial reports of a company GeoVax Labs (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.3 - $ 7.09 M chinaChina
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 5.01 6.26 % $ 831 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.26 0.31 % $ 252 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.06 -6.19 % $ 293 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.27 -3.93 % $ 588 M israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.88 -1.53 % $ 914 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.31 0.4 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.18 -2.93 % $ 7.65 B australiaAustralia
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.01 1.65 % $ 2.84 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CorMedix CorMedix
CRMD
$ 11.08 -3.57 % $ 564 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 57.6 1.62 % $ 4.86 B schweizSchweiz
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.39 -4.03 % $ 2.05 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 94.09 -0.76 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.23 3.8 % $ 1.27 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 10.87 0.65 % $ 1.41 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.57 0.05 % $ 140 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 16.36 -2.07 % $ 420 M usaUSA
Exelixis Exelixis
EXEL
$ 41.5 1.5 % $ 12 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 4.48 0.82 % $ 246 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 551.02 -2.35 % $ 41.7 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.37 3.04 % $ 14.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.14 1.46 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.88 -1.33 % $ 1.46 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.43 -0.87 % $ 739 M usaUSA
Biogen Biogen
BIIB
$ 173.99 -0.06 % $ 25.3 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.13 -4.38 % $ 110 M usaUSA